WallStSmart
SRZN

Surrozen Inc

NASDAQ: SRZN · HEALTHCARE · BIOTECHNOLOGY

$30.66
-11.73% today

Updated 2026-06-05

Market cap
$280.97M
P/E ratio
P/S ratio
37.49x
EPS (TTM)
$-36.59
Dividend yield
52W range
$8 – $35
Volume
0.1M

Surrozen Inc (SRZN) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item2019202020212022202320242025
Revenue$0.00$0.00$12.50M$12.50M$10.65M$3.48M
Revenue growth (YoY)+0.0%-14.8%-67.4%
Cost of revenue$2.93M$3.30M$3.27M$27.23M$1.44M$537000.00
Gross profit$-2.93M$-3.30M$12.50M$-27.23M$10.65M$2.94M
Gross margin100.0%-217.8%100.0%84.6%
R&D$19.60M$25.68M$40.18M$37.01M$27.23M$21.13M$29.36M
SG&A$5.50M$7.12M$14.21M$19.83M$15.80M$15.06M$16.20M
Operating income$-25.11M$-32.81M$-54.39M$-44.34M$-45.78M$-25.54M$-42.09M
Operating margin-354.7%-366.2%-239.7%-1210.6%
EBITDA$-22.82M$-31.37M$-52.33M$-42.38M$-41.13M$-24.10M$-41.55M
EBITDA margin-339.1%-329.0%-226.2%-1195.1%
EBIT$-25.11M$-34.30M$-54.39M$-44.34M$-43.04M$-25.54M$-42.09M
Interest expense$0.00$91000.00$2.07M$1.96M
Income tax$-91000.00$-2.14M$-8.34M$2.75M$-63.56M
Effective tax rate0.0%0.3%3.9%23.2%-6.8%50.0%0.0%
Net income$-24.36M$-32.63M$-52.51M$-27.67M$-43.04M$-63.56M$-242.03M
Net income growth (YoY)-33.9%-61.0%+47.3%-55.6%-47.7%-280.8%
Profit margin-221.4%-344.3%-596.6%-6960.8%

Frequently asked questions

What is Surrozen Inc's revenue?

Surrozen Inc's trailing twelve-month revenue is $7.49M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is SRZN?

In its most recent fiscal year, SRZN ran a gross margin of 84.56%, an operating margin of -1,210.58%, and a net margin of -6,960.77%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does SRZN generate?

SRZN produced $-30.37M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is SRZN's balance sheet healthy?

SRZN holds $89.25M in cash and equivalents against — in long-term debt, on $-187.76M of shareholder equity. That debt is best read against the cash flow the business throws off each year.